Renasant Bio (Renasant), announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure.

Renasant is developing a pipeline of oral small molecule corrector and first-in-class potentiator therapies that directly target the underlying biology of ADPKD, with the goal of restoring the function of key polycystin proteins across multiple different mutations to halt disease progression.

Renasant has raised $54.5 million in seed funding, co-led by founding investor 5AM Ventures, alongside other leading life sciences investors including Atlas Venture, OrbiMed and Qiming Ventures.